greeksoup/ stock research
Stock research / United States / Funds / TCG Crossover Management, LLC

TCG Crossover Management, LLC

CIK 1839948 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

TCG Crossover Management, LLC reported 54 US-listed holdings worth $4.16 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Abivax SA (19.2%), Tango Therapeutics Inc. (6.8%) and CG Oncology Inc. (6.3%). Against the quarter before, it opened 12 positions, added to 2, trimmed 9 and sold out of 7.

Reported holdings$4.16B+19.0% on Q1 2026
Positions54+5 on Q1 2026
The largest ten57.4%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedHeldTrimmed
ABVX19.2%TNGX6.8%CGON6.3%COGT4.5%IMVT4.1%SYRE4.1%DNTH3.9%MIRM3.0%ZLAB2.8%AMLX2.7%GLUE2.7%BCRX2.6%VOR2.5%TYRA2.5%40 more32.2%

The 14 largest of its 54 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $1.18 billion in 36 positions$1.18BQ3 24Q4 2024: $1.02 billion in 38 positions$1.02BQ4 24Q1 2025: $733.1 million in 38 positions$733MQ1 25Q2 2025: $875.5 million in 38 positions$876MQ2 25Q3 2025: $2.03 billion in 40 positions$2.03BQ3 25Q4 2025: $3.02 billion in 43 positions$3.02BQ4 25Q1 2026: $3.50 billion in 49 positions$3.50BQ1 26Q2 2026: $4.16 billion in 54 positions$4.16BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 12Added 2Held 31Trimmed 9Sold out 7
Opened: 12Added: 2Held: 31Trimmed: 9Sold out: 7

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 12

  1. Zai Lab Limited ZLAB$116.6 million
  2. Aura Biosciences Inc. AURA$67.7 million
  3. First Tracks Biotherapeutics TRAX$58.3 million
  4. Editas Medicine, Inc. EDIT$36.0 million
  5. Pharvaris N V PHVS$34.9 million
  6. Inflarx NV IFRX$32.5 million
  7. Altimmune, Inc. (alt) ALT$30.4 million
  8. Aktis Oncology Inc. AKTS$22.5 million

and 4 more in the table below

Added to 2

  1. Avalo Therapeutics Inc. AVTX+2.3 million shares · +309%
  2. Monopar Therapeutics Inc. MNPR+71,224 shares · +54%

Trimmed 9

  1. Abivax SA ABVX-473,251 shares · -7%
  2. Tango Therapeutics Inc. TNGX-1.4 million shares · -14%
  3. Revolution Medicines, Inc. RVMD-235,574 shares · -41%
  4. Biohaven Ltd BHVN-2.9 million shares · -62%
  5. Alx Oncology Holdings Inc. ALXO-7.4 million shares · -57%
  6. Arvinas Inc. ARVN-1.7 million shares · -70%
  7. LB Pharmaceuticals Inc. LBRX-392,179 shares · -21%
  8. Entrada Therapeutics Inc. TRDA-1.2 million shares · -54%

and 1 more in the table below

Sold out of 7

  1. Centessa Pharmaceuticals PLC CNTA$170.3 million last quarter
  2. Fulcrum Therapeutics Inc. FULC$40.3 million last quarter
  3. Liquidia Corp. LQDA$15.2 million last quarter
  4. Urogen Pharma Ltd URGN$7.3 million last quarter
  5. Structure Therapeutics Inc. GPCR$6.8 million last quarter
  6. Upstream Bio Inc. UPB$1.6 million last quarter
  7. Vistagen Therapeutics Inc. VTGN$1.5 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Abivax SA ABVX6,007,834$800.6 million19.24%-473,251
Tango Therapeutics Inc. TNGX9,081,201$283.9 million6.82%-1,449,870
CG Oncology Inc. CGON3,670,206$260.8 million6.27%no change
Cogent Biosciences Inc. COGT4,854,436$187.9 million4.52%-92,458
Immunovant Inc. IMVT4,457,988$171.8 million4.13%no change
Spyre Therapeutics Inc. SYRE1,900,582$168.7 million4.06%no change
Dianthus Therapeutics Inc. DNTH1,676,624$163.4 million3.93%no change
Mirum Pharmaceuticals Inc. MIRM1,062,049$124.3 million2.99%no change
Zai Lab Limited ZLAB6,137,627$116.6 million2.80%new
Amylyx Pharmaceuticals Inc. AMLX6,243,812$112.1 million2.70%no change
Monte Rosa Therapeutics Inc. GLUE4,622,151$111.9 million2.69%no change
Biocryst Pharmaceuticals Inc. BCRX11,020,968$110.2 million2.65%no change
Vor Biopharma Inc. VOR5,673,078$104.4 million2.51%no change
Tyra Biosciences Inc. TYRA3,248,980$103.8 million2.49%no change
Dyne Therapeutics Inc. DYN4,615,144$102.5 million2.46%no change
Disc Medicine Inc. IRON1,341,862$98.1 million2.36%no change
Relay Therapeutics Inc. RLAY4,273,356$80.0 million1.92%no change
Savara Inc. SVRA12,362,205$76.2 million1.83%no change
Aura Biosciences Inc. AURA9,533,333$67.7 million1.63%new
Revolution Medicines, Inc. RVMD340,899$63.8 million1.53%-235,574
First Tracks Biotherapeutics TRAX2,895,304$58.3 million1.40%new
Kodiak Sciences Inc. KOD1,445,538$56.3 million1.35%no change
Avalo Therapeutics Inc. AVTX3,017,120$55.8 million1.34%+2,278,737
LB Pharmaceuticals Inc. LBRX1,447,310$47.0 million1.13%-392,179
Century Therapeutics Inc. IPSC17,754,430$43.4 million1.04%no change
Tectonic Therapeutic Inc. TECX1,204,891$41.4 million1.00%no change
Xencor Inc. XNCR2,452,138$39.5 million0.95%no change
Surrozen Inc. SRZN1,473,101$38.2 million0.92%no change
Editas Medicine, Inc. EDIT11,111,111$36.0 million0.87%new
MBX Biosciences Inc. MBX650,000$35.9 million0.86%no change
Pharvaris N V PHVS1,008,229$34.9 million0.84%new
Silence Therapeutics PLC SLN3,033,560$33.3 million0.80%no change
Inflarx NV IFRX14,500,000$32.5 million0.78%new
Altimmune, Inc. (alt) ALT10,000,000$30.4 million0.73%new
Janux Therapeutics Inc. JANX1,789,617$27.5 million0.66%no change
Perspective Therapeutics Inc CATX7,915,567$27.0 million0.65%no change
Agomab Therapeutics NV AGMB2,053,233$26.7 million0.64%no change
Biohaven Ltd BHVN1,779,952$26.5 million0.64%-2,851,365
Aktis Oncology Inc. AKTS696,560$22.5 million0.54%new
Alector Inc. ALEC10,000,000$20.1 million0.48%no change
Forte Biosciences Inc. FBRX920,000$19.6 million0.47%new
Monopar Therapeutics Inc. MNPR203,327$18.8 million0.45%+71,224
Ocular Therapeutix Inc. OCUL1,647,752$16.2 million0.39%no change
Auven Therapeutics Management ADCT11,390,175$12.2 million0.29%no change
Alx Oncology Holdings Inc. ALXO5,655,487$11.7 million0.28%-7,356,362
Entrada Therapeutics Inc. TRDA1,060,230$7.8 million0.19%-1,227,270
Cullinan Therapeutics Inc. CGEM406,786$7.4 million0.18%no change
Arvinas Inc. ARVN707,098$5.9 million0.14%-1,680,363
Korro Bio Inc. KRRO416,301$5.5 million0.13%no change
Research Alliance Corp Iii Ord Shs Cl A RACC500,000$5.3 million0.13%new
Athira Pharma Inc. LONA464,398$4.3 million0.10%no change
Jatt II Acquisition Corp. JATT200,000$2.3 million0.05%new
Context Therapeutics Inc. CNTX2,682,696$1.5 million0.04%no change
Eikon Therapeutics Inc. EIKN37,902$494,6210.01%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 7 it sold out of are in the box above.